Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$2.85 - $5.18 $5,130 - $9,324
1,800 Added 11.46%
17,500 $57,000
Q4 2021

Feb 09, 2022

BUY
$14.7 - $19.89 $230,790 - $312,273
15,700 New
15,700 $247,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $720M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Letko, Brosseau & Associates Inc Portfolio

Follow Letko, Brosseau & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Letko, Brosseau & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Letko, Brosseau & Associates Inc with notifications on news.